Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport (CYRX) reported third-quarter 2026 revenue of $50.2 million, up 14% year over year, and raised its full-year revenue outlook. The company now expects $197 million to $199 million in 2026 revenue. Quarterly Life Sciences Services revenue increased 18%, while Life Sciences Products revenue rose 8%. Commercial cell and gene therapy revenue grew 20%.
The quarterly loss from continuing operations widened to $10.9 million from $6.7 million, while adjusted EBITDA from continuing operations, a non-GAAP earnings measure, improved to $1.1 million from negative $0.6 million. Gross margin fell to 47.5% from 48.2%. Nine-month revenue rose 12% to $147.0 million. At September 30, Cryoport supported 788 clinical trials and 23 commercial therapies and held $393.1 million in cash, cash equivalents and short-term investments.
Cryoport (CYRX) will report its third-quarter 2026 financial results on November 5, 2026, after U.S. markets close. The results cover the quarter ended September 30, 2026.
A review of operational developments, business milestones and strategic initiatives will be issued at 4:05 p.m. ET, ahead of management's 5:00 p.m. ET question-and-answer conference call that day. A slide deck will accompany the call. A recording will be available on the company's investor relations website approximately three hours after the live event ends, for a limited time.
Cryoport (NASDAQ: CYRX) reported Q2 2026 revenue of $49.0 million, up 8% year-over-year, with H1 2026 revenue of $96.8 million, up 12%. Life Sciences Services grew 15% in Q2 to $28.0 million, driven by 25% growth in BioStorage/BioServices to $5.6 million, while Life Sciences Products was flat at $21.0 million.
Total gross margin was 46.6% in Q2 (46.2% H1). Loss from continuing operations narrowed to $8.3 million from $12.0 million, and adjusted EBITDA from continuing operations turned positive at $0.4 million versus a negative $0.9 million. Net loss attributable to common stockholders was $10.3 million, or $0.20 per share, compared with prior-year profit that was largely driven by the 2025 CRYOPDP divestiture. Cryoport ended the quarter with $396.7 million in cash, cash equivalents, and short-term investments, supported 779 clinical trials and 22 commercial CGT therapies, and highlighted progress on new Global Supply Chain Centers and additional regulatory milestones across its customer base.
Cryoport (Nasdaq: CYRX) will report its financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026, after U.S. markets close. A detailed document, “Cryoport Second Quarter 2026 in Review,” covering financial, operational performance and a general business update, will be released at 4:05 p.m. ET the same day on the company’s investor relations site.
Cryoport management will host a Q&A-format conference call on August 6, 2026 at 5:00 p.m. ET, accompanied by a slide deck and a live webcast accessible via the Investor Relations section of www.cryoportinc.com. U.S. participants can dial 1-800-717-1738, while international participants can dial 1-646-307-1865, requesting the “Cryoport Call” or Conference ID 1142151. A webcast replay will be available on the company’s website, and a dial-in replay will be offered until August 13, 2026 at 1-844-512-2921 (U.S.) or 1-412-317-6671 (International) using replay code 1142151#.
Cryoport (NASDAQ: CYRX) announced that its IntegriCell® cryopreservation services were selected by Verismo Therapeutics to support clinical KIR-CAR T cell therapy programs SynKIR™-110 and SynKIR™-310.
IntegriCell provides manufacture-ready leukapheresis starting material within a global GMP-compliant system, with service centers in Houston and Liège integrated into Cryoport’s broader temperature-controlled supply chain platform.
Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8M, up 16% year‑over‑year, and raised full‑year revenue guidance to $192M–$196M. Commercial CGT revenue grew 26% to $9.1M; the company supported 766 clinical trials and 21 commercial therapies as of March 31, 2026. Adjusted EBITDA from continuing operations improved by $2.2M year‑over‑year to negative $0.6M. Cash and short‑term investments totaled $403.6M. Operational expansions planned in Paris (Q3) and Santa Ana (Q4) 2026.
Cryoport (Nasdaq: CYRX) will report first quarter 2026 financial results after U.S. markets close on Monday, May 4, 2026. A "Cryoport First Quarter 2026 in Review" document will be released at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET.
A slide deck will accompany the call; a live webcast and dial-in details are available on the company's Investor Relations site, and replays will be posted and available by phone through May 11, 2026.
Cryoport (NASDAQ: CYRX) reported FY2025 revenue of $176.2 million, up 12% year-over-year and above prior guidance, with Life Sciences Services revenue of $96.5 million (+18%) and Life Sciences Products revenue of $79.7 million (+7%).
The company supported a record 760 clinical trials and 20 commercial therapies, ended FY2025 with $411.2 million in cash and provided 2026 revenue guidance of $190.0M–$194.0M (8%–10% growth).
Cryoport (Nasdaq: CYRX) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026 after U.S. markets close.
Management will issue a review document at 4:05 p.m. ET and host a questions-and-answers conference call at 5:00 p.m. ET with an accompanying slide deck; replay available through March 10, 2026.
Cryoport (NASDAQ: CYRX) launched the MVE Fusion® 800 Series, a lab-sized self-sustaining cryogenic freezer designed for space-constrained environments. The Fusion 800 eliminates the need for a continuous liquid nitrogen supply, delivers steady-state temperatures at or below -150°C, and fits through standard doorways at 32 inches wide. The technology is ISBER award-winning and aimed at research facilities, hospital pharmacies, biorepositories, and blood and tissue banks.